Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06226571 · ClinicalTrials.gov registry record · Phase 1
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
A Phase 1 study of Acute Myeloid Leukemias, sponsored by Syndax Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT06226571 is a Phase 1 study of Acute Myeloid Leukemias that is actively recruiting participants, run by Syndax Pharmaceuticals. The registered enrollment target is 76 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06226571, a Phase 1 study of Acute Myeloid Leukemias, is actively recruiting participants, sponsored by Syndax Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Conditions Studied
Interventions
- DRUG SNDX-5613
- DRUG Chemotherapy Regimen
- DRUG HiDAC
Study Locations (20)
New York
- Institution name: Northwell Health-Brany - Lake Success
- Memorial Sloan Kettering Cancer Center - New York
- University of Rochester Medical Center - Rochester
- SUNY Upstate Medical University - Syracuse
California
- UCLA Medical Hematology - Burbank
- City of Hope Medical Center - Duarte
Florida
- AdventHealth Blood & Marrow Transplant Center - Orlando
- Tampa General Hospital - Tampa
Kentucky
- University of Louisville Health Brown Cancer Center - Louisville
- Norton Cancer Institute, St. Matthews Campus - Louisville
North Carolina
- East Carolina University - Greenville
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Georgia
- Emory Winship Cancer Institute - Atlanta
Illinois
- University of Chicago - Chicago
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2024-05-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06226571
The ClinicalTrials.gov registry entry for NCT06226571 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Myeloid Leukemias appearing as the primary indexed condition, and to 3 interventions - of which SNDX-5613 is the first listed.
NCT06226571 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06226571 about?
NCT06226571 is a clinical study titled "A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
What is the current status of trial NCT06226571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2024-05-21. Estimated completion is 2027-02.
What conditions does trial NCT06226571 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemias.
What interventions are being tested in trial NCT06226571?
The interventions under investigation include: SNDX-5613 (DRUG), Chemotherapy Regimen (DRUG), HiDAC (DRUG).
Who is sponsoring clinical trial NCT06226571?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06226571 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.